Bioconjugates, ADCs & Chemistry - Abzena

Leading Biologics, Bioconjugates & ADC CDMO

Specialized complex biologics, bioconjugate and antibody-drug conjugate (ADC) development and manufacturing services.

For over 20 years Abzena has provided integrated, end-to-end solutions and services that accelerate biologics, bioconjugate, and ADC development and manufacturing. Our unique approach helps make us far more than a traditional Contract Development & Manufacturing Organization (CDMO).

Taking the decision to work with a CDMO partner is challenging, and amongst the most crucial early decisions you will make on your molecule’s development. Abzena are ready to work together with you to de-risk and streamline the development and manufacture of your novel treatments so that you can rapidly bridge from discovery through commercial launch.

We offer a uniquely collaborative, personalized, and transparent partnership differentiated by our values and insights gained from over 20 years of experience and multiple decades of scientific knowledge.

We offer best-in-class biologics, bioconjugates and ADC CDMO + CRO services along with a highly detailed and personalized experience. Contact us today to find out more about our expanding ADC capabilities.

Extensive R&D capabilities with over 20 years of biologics, bioconjugates, & ADC CDMO experience

From biologics design to ADC developability, through to commercial manufacturing, Abzena offer integrated contract research, development, and manufacturing services for many of the leading pharma and biotech customers. Our scientific experts at our locations in Cambridge UK, Bristol and San Diego USA have experience working with hundreds of molecules across all stages of the drug development process.

ThioBridge®: Antibody Drug Conjugation (ADC) Platform Technology

Enhance your ADC development with our ThioBridge® conjugation platform technology.

ADC & Bioconjugation Services

Abzena has over 20 years of expertise in identifying and mapping the appropriate design space for the development of your complex antibody-drug conjugates (ADCs). Through our developability assessments, we identify and de-risk your clinical candidates for development, ensuring that your timescales are met.